A Sanofi plant in London that has been slated for closure has manufactured its last batch of drugs. Its equipment will be pulled out and moved to plants in Germany and Italy, and most of its 450 workers are set to lose their jobs by the end of the month.
Now that Plavix and Lipitor are down for the count, AstraZeneca's Nexium is the reigning heavyweight drug champion. According to Drugs.com, the stomach drug outsold all other branded drugs during the second quarter, with $1.38 billion in revenues. But Nexium's dominance could be short-lived.
Pfizer's success with co-pay coupons has encouraged other blockbuster-losing Big Pharmas to follow suit. Have the others been able to replicate Pfizer's experience? Yes and no, according to the Associated Press.
It's not a megabrand like Lipitor or Plavix, but the diabetes drug Actos has brought in more than $3 billion in U.S. sales at its peak, more than $16 billion total since its release in 1999. And now, it has generic competition. Takeda Pharmaceuticals, watch your back.
They're playing a dirge at Merck today, for their blockbuster asthma-and-allergy drug Singulair. The FDA approved a host of generic competitors Friday. So, today, the decline begins--and it's likely to be swift.
Sanofi's earnings are a half-full, half-empty situation. Yes, the company beat analyst expectations, but analyst expectations were low to begin with.
If today's pharma sales reports look grim, none is so grim as Bristol-Myers Squibb's. The company's loss of exclusivity on its top-selling drug Plavix helped push U.S. sales down by 27%.
Leave it to a patent expiration to trigger musical chairs at the top of pharma sales rankings. Plavix is now the biggest-selling drug in the U.S., after stealing the crown from Pfizer's newly off-patent Lipitor, PM Live reports.
For a company that is cutting jobs by the thousands, adding 40 new positions at a manufacturing plant in England might seem like small potatoes, but not so to the management at Sanofi's ($SNY) Holmes Chapel operation.
AstraZeneca doesn't shy from a challenge. The drugmaker ($AZN) has launched a study comparing its clot-fighter Brilinta with the standard bloodthinner treatment Plavix, in patients with peripheral artery disease.